Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

about

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

Item

http://www.wikidata.org/entity/Q54987182

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

@en

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

@nl

type

Item

label

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

@en

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

@nl

prefLabel

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

@en

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

@nl

P1476

Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer

@en

P2093

Sandra M E Geurts

http://www.w3.org/2001/XMLSchema#string

Vivianne C G Tjan-Heijnen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Practical methods for incorporating summary time-to-event data into meta-analysis

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Adjuvant ovarian suppression in premenopausal breast cancer.

Aromatase inhibitors in breast cancer.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.

P2888

s11864-018-0541-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-018-0541-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Irene E G van Hellemond

P577

2018-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29704066

http://www.w3.org/2001/XMLSchema#string

P921

local neoplasm recurrence

breast neoplasm

P932

5937869

http://www.w3.org/2001/XMLSchema#string